Omer Abdul Hamid
Neurology with Special Qualifications in Child Neurology · Orlando, FLNPI 1780048397
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (32.6%), grants and consulting fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Biogen at 44.2% of the total. Among neurology with special qualifications in child neurology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 287 payments — averaging $984.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$125K
- Genentech USA, Inc.$73K
- Sarepta Therapeutics, Inc.$53K
- Catalyst Pharmaceuticals, Inc.$11K
- ITF Therapeutics LLC$6K
- PTC Therapeutics, Inc.$5K
- plus $9K from 17 others
Across 36 payments — averaging $5138.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$155K
- Sarepta Therapeutics, Inc.$30K
What the payments were for
- Consulting fees$70,02725%
- Speaking & faculty fees$92,08433%
- Grants$90,00032%
- Travel & lodging$19,1657%
- Food & beverage$11,2304%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 59 | $124,912 |
| Genentech USA, Inc. | 67 | $73,112 |
| Sarepta Therapeutics, Inc. | 67 | $52,939 |
| Catalyst Pharmaceuticals, Inc. | 18 | $11,268 |
| ITF Therapeutics LLC | 9 | $6,138 |
| PTC Therapeutics, Inc. | 2 | $4,808 |
| Pfizer | 3 | $3,823 |
| UCB, Inc. | 7 | $2,043 |
| Genentech, Inc. | 14 | $1,022 |
| Livanova USA, Inc. | 4 | $761 |
| Acadia Pharmaceuticals Inc | 7 | $360 |
| NS Pharma, Inc. | 9 | $326 |
| Immedica Pharma US, Inc. | 3 | $255 |
| Novartis | 3 | $245 |
| AstraZeneca | 1 | $130 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 3 | $116 |
| Jazz Pharmaceuticals Inc. | 3 | $73 |
| Biocodex, Inc. | 2 | $62 |
| Intrabio Inc | 1 | $34 |
| Eisai Inc. | 2 | $30 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Neurelis, Inc. | 1 | $17 |
| Biomarin Pharmaceutical Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$282,506 in reported general payments places this provider in the 95th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Other neurology with special qualifications in child neurology in Orlando
- Ngoc Minh leOrlando$19K
- Vikram PrakashOrlando$15K
- Ki-Hyeong LeeOrlando$15K
- Sheila Ramos MartinezOrlando$8K
- Anthony GiordanoOrlando$7K
- Murtuza KothawalaOrlando$5K
- Carl BarrOrlando$5K
- Dina DahanOrlando$5K
- Antonio Vazquez-DiazOrlando$5K
- Paul WinnerWest Palm Beach$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.